Golden Throat Holdings Group Company Limited (6896.HK)
HKD 4.18
(-0.24%)
HKD 4.18
(-0.24%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | - CNY | 0.0% |
| 2022 | - CNY | 0.0% |
| 2021 | - CNY | 0.0% |
| 2020 | - CNY | 100.0% |
| 2019 | -182 Thousand CNY | 38.1% |
| 2018 | -294 Thousand CNY | 0.0% |
| 2017 | - CNY | 0.0% |
| 2016 | - CNY | 0.0% |
| 2015 | - CNY | 0.0% |
| 2014 | - CNY | 0.0% |
| 2013 | - CNY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 Q4 | - CNY | 0.0% |
| 2023 FY | - CNY | 0.0% |
| 2023 Q2 | - CNY | 0.0% |
| 2022 Q4 | - CNY | 0.0% |
| 2022 FY | - CNY | 0.0% |
| 2022 Q2 | - CNY | 0.0% |
| 2021 Q4 | - CNY | 0.0% |
| 2021 FY | - CNY | 0.0% |
| 2021 Q2 | - CNY | 0.0% |
| 2020 Q4 | - CNY | 0.0% |
| 2020 Q2 | - CNY | 100.0% |
| 2020 FY | - CNY | 100.0% |
| 2019 FY | -182 Thousand CNY | 38.1% |
| 2019 Q2 | 216 Thousand CNY | 173.47% |
| 2019 Q4 | -182 Thousand CNY | -184.26% |
| 2018 Q4 | -294 Thousand CNY | 0.0% |
| 2018 FY | -294 Thousand CNY | 0.0% |
| 2018 Q2 | - CNY | 0.0% |
| 2017 Q4 | - CNY | 0.0% |
| 2017 FY | - CNY | 0.0% |
| 2017 Q2 | - CNY | 0.0% |
| 2016 Q2 | - CNY | 0.0% |
| 2016 Q4 | - CNY | 0.0% |
| 2016 FY | - CNY | 0.0% |
| 2015 FY | - CNY | 0.0% |
| 2015 Q4 | - CNY | 0.0% |
| 2015 Q2 | - CNY | -100.0% |
| 2014 FY | - CNY | 0.0% |
| 2014 Q4 | 110.98 Million CNY | 0.0% |
| 2013 FY | - CNY | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 2.07 Million HKD | 100.0% |
| Grand Pharmaceutical Group Limited | 990.02 Million HKD | 100.0% |
| Extrawell Pharmaceutical Holdings Limited | 117.12 Million HKD | 100.0% |
| Wai Yuen Tong Medicine Holdings Limited | 276.2 Million HKD | 100.0% |
| Qianhai Health Holdings Limited | - HKD | NaN% |
| Lee's Pharmaceutical Holdings Limited | 70.63 Million HKD | 100.0% |
| Essex Bio-Technology Limited | 36.05 Million HKD | 100.0% |
| Tongfang Kontafarma Holdings Limited | 12.8 Million HKD | 100.0% |
| PuraPharm Corporation Limited | 81.09 Million HKD | 100.0% |
| SSY Group Limited | 1.94 Billion HKD | 100.0% |
| JBM (Healthcare) Limited | 43.8 Million HKD | 100.0% |
| Jacobson Pharma Corporation Limited | 592.2 Million HKD | 100.0% |
| China Resources Pharmaceutical Group Limited | 16.61 Billion HKD | 100.0% |